J&J's Janssen Ends Two Aduro Cancer Collaborations Launched in 2014

Johnson & Johnson’s Janssen Biotech is terminating a pair of collaborations to develop lung and prostate cancer treatments with Aduro Biotech that were launched in 2014 and could have generated more than $1.182 billion for the Berkeley, CA, immunotherapy developer, Aduro has disclosed.In a regulatory filing yesterday, Aduro acknowledged that it will regain global rights to develop and commercialize the cancer vaccines ADU-214, ADU-741, and GVAX Prostate for any and all uses, after rece